Walk into any dispensary in America and ask a budtender what makes one strain better than another. The answer, more often than not, will involve THC percentage — the single data point that has come to dominate how cannabis is marketed, priced, and purchased. Flower testing at 30% THC commands premium shelf placement and premium prices. Flower testing at 18% sits on the bottom shelf, regardless of its actual effect profile.

This THC fixation is not just reductive. According to a growing body of clinical research, it is scientifically wrong — and the concept that explains why, the entourage effect, is finally moving from dispensary folklore to a pharmacological hypothesis supported by rigorous evidence.

The THC Percentage Problem

The assumption that higher THC equals a better experience has been contradicted by every controlled study that has examined the question. A 2020 study published in JAMA Psychiatry found no correlation between THC concentration in flower and the subjective intensity of intoxication reported by participants. Users of high-potency and moderate-potency cannabis reported similar levels of impairment and euphoria.

A 2024 study from the University of Colorado Boulder’s Center for Research on Cannabis reinforced this finding with blood plasma data. Participants who consumed 24% THC flower and 16% THC flower showed nearly identical blood THC concentrations 30 minutes after consumption — suggesting that the body’s cannabinoid receptors reach a saturation point beyond which additional THC provides diminishing returns.

The implication is significant: THC percentage tells you how much THC is in the plant material, but it does not reliably predict how that product will make you feel. Something else is mediating the experience. The entourage effect hypothesis argues that the “something else” is the full spectrum of compounds working together.

What the Entourage Effect Actually Means

The term “entourage effect” was coined in 1998 by Israeli researchers Raphael Mechoulam and Shimon Ben-Shabat to describe how endogenous cannabinoid compounds in the body work synergistically. It was later expanded by neurologist Ethan Russo in a landmark 2011 paper in the British Journal of Pharmacology to encompass the interactions between phytocannabinoids (THC, CBD, CBG, CBN, and over 100 others) and terpenes (the aromatic compounds responsible for cannabis’s distinctive flavors and aromas).

The hypothesis proposes that these compounds modulate each other’s effects through several pharmacological mechanisms — all of which operate through the endocannabinoid system: direct receptor binding, allosteric modulation (changing how a receptor responds to its primary ligand), enzyme inhibition (slowing the breakdown of active compounds), and enhanced bioavailability (improving absorption and distribution).

This is not a mystical claim. These are well-characterized pharmacological mechanisms that have been documented for other plant-derived medicines. Aspirin works through a similar multi-compound synergy in willow bark. Black pepper’s piperine enhances curcumin absorption by 2,000%. The question for cannabis is not whether synergy is possible but whether the specific compounds present in the plant produce meaningful synergistic effects at the concentrations found in commercial products.

The Key Studies

The clinical evidence base has expanded significantly since Russo’s 2011 framework paper. Several lines of evidence now support the entourage effect, though the picture remains incomplete.

The most cited evidence comes from epilepsy research. A 2018 meta-analysis published in Frontiers in Neurology compared outcomes between patients treated with purified CBD (Epidiolex) and those treated with CBD-rich whole plant extracts. The whole plant extract patients achieved similar seizure reduction at significantly lower doses — a mean daily dose of 6.1 mg/kg for whole plant versus 25.3 mg/kg for purified CBD. The implication is that other compounds in the whole plant extract were enhancing CBD’s efficacy, allowing lower doses to achieve the same therapeutic effect.

A 2022 study from the University of Sydney, published in Pharmacological Research, tested combinations of THC with individual terpenes in a mouse model of inflammatory pain. The combination of THC with the terpene myrcene produced analgesia greater than either compound alone at the same dose — a textbook demonstration of pharmacological synergy. The combination with limonene showed modest enhancement, while alpha-pinene showed no significant interaction, suggesting that not all terpene-cannabinoid combinations produce synergistic effects.

A 2025 randomized controlled trial conducted by Syqe Medical in Israel — one of the first placebo-controlled human trials specifically designed to test the entourage effect — found that a standardized cannabis formulation containing THC, CBD, and a defined terpene profile produced more consistent analgesic effects than THC alone, with fewer reports of anxiety and paranoia. The sample size was modest (87 participants), but the trial design was rigorous, and the results were statistically significant.

Terpene-Cannabinoid Interactions

The terpene research has been particularly illuminating because it suggests specific, testable mechanisms for entourage effects rather than a vague notion of “everything working together.”

Myrcene, the most abundant terpene in most cannabis cultivars, has demonstrated the most consistent evidence of synergy with THC. In addition to the University of Sydney pain study, preclinical work at the Hebrew University of Jerusalem has shown that myrcene increases the permeability of the blood-brain barrier to cannabinoids — a mechanism that would explain both faster onset of effects and enhanced potency at lower doses.

Beta-caryophyllene, a terpene found in high concentrations in many cannabis cultivars as well as black pepper and cloves, is unique among terpenes because it directly binds to the CB2 cannabinoid receptor. This gives it anti-inflammatory and analgesic properties independent of THC, and preclinical data suggest it may modulate THC’s effects through receptor-level competition.

Limonene, which gives citrusy cannabis strains their characteristic aroma, has shown anxiolytic (anti-anxiety) properties in both human and animal studies. A 2023 paper in the Journal of Ethnopharmacology hypothesized that limonene-rich cannabis strains may produce less anxiety than limonene-poor strains at equivalent THC levels — a finding consistent with the common consumer report that “sativa-leaning” cultivars with citrus terpene profiles feel different from “indica-leaning” cultivars despite similar THC content.

Linalool, the primary terpene in lavender and present in many cannabis cultivars, has well-documented sedative and anxiolytic properties. Research published in the International Journal of Molecular Sciences in 2024 demonstrated that linalool enhances GABAergic neurotransmission — the same mechanism targeted by benzodiazepines — suggesting a neurochemical basis for the sedating quality of linalool-rich cannabis strains.

Why This Matters for Product Development

The practical implications for the cannabis industry are substantial. If the entourage effect is real — and the evidence increasingly says it is — then the industry’s current product development and marketing paradigm is fundamentally misaligned with the pharmacology.

The trend toward ultra-high-THC distillate products, which strip out terpenes and minor cannabinoids in pursuit of maximum potency, may be producing a worse consumer experience than full-spectrum alternatives at lower THC levels. Several brands have begun repositioning around this insight, marketing products by terpene profile and cannabinoid ratio rather than THC percentage.

The strain database concept — which Green Rush and other platforms maintain as a consumer tool — also requires reframing in light of entourage effect research. A strain’s terpene profile and minor cannabinoid content may be more predictive of its effects than its THC percentage, which means the most useful consumer information is the most granular chemical data, not the number the industry has trained everyone to focus on.

Some state regulators are beginning to respond. Colorado and California now require terpene testing on product labels, and several states are considering regulations that would restrict THC potency marketing claims or require more comprehensive chemical profiles on packaging.

What We Still Don’t Know

Intellectual honesty requires acknowledging the limitations of the current evidence. The entourage effect hypothesis is supported by a growing body of research, but the evidence base is still incomplete.

Most of the terpene-cannabinoid interaction data comes from preclinical studies — animal models and cell cultures — rather than randomized human trials. The concentrations of terpenes used in laboratory studies do not always reflect the concentrations present in commercial cannabis products after combustion or vaporization, where thermal degradation significantly alters the terpene profile.

The 2025 Syqe Medical trial is a step toward rigorous human evidence, but the field needs larger, multi-site trials with standardized products and longer follow-up periods. The difficulty of conducting cannabis research in the United States — a consequence of Schedule I classification that rescheduling will partially alleviate — has limited the pace of clinical progress.

The entourage effect also likely varies significantly between individuals based on genetics, tolerance, endocannabinoid system function, and consumption method. A terpene-cannabinoid combination that produces synergistic effects for one person may be unremarkable for another.

What the evidence does support, clearly and consistently, is that THC percentage alone is an inadequate predictor of cannabis effects — and that the hundreds of other compounds in the plant are not biochemical passengers. They are active participants in a complex pharmacological interaction that the industry is only beginning to understand and that consumers deserve to know about.